A. Nazaretian

Establishment and genomic validation of novel patient-derived xenograft models for drug discovery in gastrointestinal stromal tumor

Most gastrointestinal stromal tumor (GIST) patients develop clinical resistance to approved tyrosine kinase inhibitors (TKI). The development of effective treatment strategies for refractory GIST requires identification of novel targets for investigational agents and well-characterized preclinical models, like pati...